NLRP3 and cryopyrin-associated periodic syndrome: Two such NLRP3 antagonists, namely IZD334 (ClinicalTrials.gov Identifier: NCT04086602) and Inzomelid (ClinicalTrials.gov Identifier: NCT04015076), have recently completed early clinical testing to assess the safety, tolerability, and pharmacological properties of the drugs in healthy adult participants and to obtain first evidence of clinical efficacy in adult CAPS patients (Figure 3).